Take­da starts to as­sem­ble a list of prod­ucts it plans to auc­tion off af­ter Shire buy­out — re­port

First comes the big M&A deal. Then comes the prod­uct sales to help pay for it.

Bloomberg this morn­ing re­ports that Take­da is al­ready con­sid­er­ing what it wants to put up for sale, ahead of clos­ing on its $62 bil­lion Shire buy­out. And oph­thal­mol­o­gy — a group near and dear to the heart of Shire CEO Flem­ming Orn­skov — looks like it’s head­ed for the auc­tion block.

The dry eye ther­a­py Xi­idra (li­fite­grast), one of the po­ten­tial block­buster drugs that Orn­skov steered to an ap­proval in 2016, is on the list of pos­si­ble di­vest­ments, sources tell the busi­ness news group. And Nat­para — sold to treat low blood cal­ci­um as­so­ci­at­ed with de­creased parathy­roid hor­mone — is al­so on the list.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER